Insights of Fabry disease: Expert consensus approach for screening, diagnosis, and multidisciplinary management in chronic kidney disease
Journal of the Formosan Medical Association · 2025
DOI: 10.1016/j.jfma.2024.09.033 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the Formosan Medical Association, 2025. Verfasst von Cheng-Jui Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Fabry Disease, Renal Insufficiency, Chronic, Mass Screening. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The prevalence of Fabry disease (FD) among males with chronic kidney disease (CKD) of unknown etiology in Taiwan is 0.6%. Despite this, FD is frequently overlooked in clinical settings. To address this issue, two consensus meetings were conducted in Taiwan-one in August 2022 and another in April 2023. The first meeting established screening criteria based on age, gender, family history, cardiac involvement, and symptoms. The second meeting, with a multidisciplinary team, developed treatment recommendations. The consensus emphasizes the importance of proactive data collection in dialysis units and outpatient follow-ups to enhance FD detection and management. The screening algorithm recommends incorporating FD screening into the diagnostic process for CKD patients, regardless of age. Priority is given to patients with a family history of FD, early stroke history, or classical FD symptoms. Comprehensive screening is also advised for CKD patients without obvious classical symptoms. Screening protocols for males include measuring α-galactosidase A enzyme activity, with reduced activity leading to further tests such as lyso-Gb3 level quantification and genetic analysis. For females, the protocol involves evaluating lyso-Gb3 plasma levels and genetic testing. FD, though often underestimated, is more prevalent than recognized and necessitates a multidisciplinary approach for timely diagnosis. Enhancing awareness and adopting a comprehensive approach are essential for improving patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan.
- Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan; Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; College of Medicine, Nat…
- Division of Nephrology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan. Electronic address: yaliwcj@gmail.com.
- Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, T…
- Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Zitieren
APA
Lin, C. J., Yang, F. J., Wu, C. J., Wu, M. J., & Wu, M. S. (2025). Insights of Fabry disease: Expert consensus approach for screening, diagnosis, and multidisciplinary management in chronic kidney disease. Journal of the Formosan Medical Association. https://doi.org/10.1016/j.jfma.2024.09.033
Vancouver
Lin CJ, Yang FJ, Wu CJ, Wu MJ, Wu MS. Insights of Fabry disease: Expert consensus approach for screening, diagnosis, and multidisciplinary management in chronic kidney disease. Journal of the Formosan Medical Association. 2025. doi:10.1016/j.jfma.2024.09.033
BibTeX
@article{Lin2025,
author = {Lin, Cheng-Jui and Yang, Feng-Jung and Wu, Chih-Jen and Wu, Ming-Ju and Wu, Mai-Szu},
title = {Insights of Fabry disease: Expert consensus approach for screening, diagnosis, and multidisciplinary management in chronic kidney disease},
journal = {Journal of the Formosan Medical Association},
year = {2025},
doi = {10.1016/j.jfma.2024.09.033}
}
EUVIMED